AI Article Synopsis
- The Open University held its first one-day symposium on neuroendocrine prostate cancer, bringing together leading experts and researchers from various fields.
- The event highlighted the growing incidence of this type of cancer, linked to the use of new androgen deprivation therapies, and addressed current challenges in its diagnosis and treatment.
- Discussions focused on establishing new molecular research targets to enhance treatment options and speed up progress in understanding this serious yet often overlooked condition.
Article Abstract
The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer attracted world-leading figures, early career researchers and industry colleagues. The symposium proved insightful into the 'real-world' impact and current problems faced in the diagnosis and treatment of neuroendocrine prostate cancer. It was important for this meeting to take place as the incidence of neuroendocrine prostate cancer is increasing due to the widespread use of next-generation androgen deprivation drugs. The symposium discussions proposed new molecularly driven deadlines to accelerate research and improved the treatment of this deadly and poorly recognized malignancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2019-0718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!